Analysts Set Repligen Corporation (NASDAQ:RGEN) PT at $177.92

Shares of Repligen Corporation (NASDAQ:RGEN) have earned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $177.9167.

A number of equities analysts recently commented on RGEN shares. Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday. Canaccord Genuity Group increased their target price on Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a report on Wednesday, October 29th. Barclays upped their price target on Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Jefferies Financial Group set a $160.00 price objective on shares of Repligen and gave the stock a “hold” rating in a report on Tuesday, October 28th. Finally, UBS Group boosted their target price on shares of Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 16th.

Insider Buying and Selling

In other news, Director Karen A. Dawes sold 275 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the transaction, the director directly owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. This represents a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in RGEN. AQR Capital Management LLC bought a new stake in Repligen in the first quarter valued at $262,000. Jones Financial Companies Lllp lifted its position in Repligen by 3,850.6% in the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after purchasing an additional 6,238 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Repligen by 16.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after purchasing an additional 20,375 shares during the period. TD Asset Management Inc grew its position in Repligen by 54.8% in the 2nd quarter. TD Asset Management Inc now owns 79,224 shares of the biotechnology company’s stock worth $9,854,000 after purchasing an additional 28,052 shares during the last quarter. Finally, Angeles Wealth Management LLC bought a new position in Repligen in the 2nd quarter worth about $209,000. 97.64% of the stock is currently owned by institutional investors.

Repligen Trading Up 2.0%

NASDAQ RGEN opened at $138.11 on Monday. Repligen has a 12 month low of $102.96 and a 12 month high of $175.77. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14. The company has a market capitalization of $7.77 billion, a price-to-earnings ratio of 6,908.95, a price-to-earnings-growth ratio of 2.47 and a beta of 1.13. The company’s fifty day moving average price is $157.73 and its two-hundred day moving average price is $146.03.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.